Released Nov 7, 2019, after the close
10-Q filed Nov 7, 2019, 38 days after period end · 0000950123-19-010301
Q3 2019 · 10-Q
Revenue$4.23M$4.23M −1.3% vs Q3 2018+37.4% vs Q2 2019
Net Income-$25.00M-$25.00M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.96-$0.96 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$25,993,000N/M
Operating Cash Flowderived-$18,595,000N/M
Free Cash Flowderived-$18,595,000N/M
Margins · derived
Operating margin-614.3%−87.6 pt vs Q3 2018
Net margin-590.8%−88.3 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $4.23M | $4.29M | $2.66M | — |
| Net Income | -$25.00M | -$21.54M | -$12.27M | -$11.57M |
| EPS Diluted | -$0.96 | -$0.87 | -$710.00 | -$0.67 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR